Sanofi-Aventis, the world’s third-largest pharmaceutical company, has awarded a significant part of its advertising business to Havas-owned Euro RSCG.
The company, which has its HQ in France, has appointed Euro RSCG Life, the network’s health division, to oversee communications for its new diabetes brands Lantus and Apidra, and its thrombosis treatment Lovenox/Clexane.
Euro RSCG Life has also been handed responsibility for launching all future marketing programmes for new brands within these two product areas.
It is understood that the account is moving out of Publicis into the Havas-owned network, with Sanofi-Aventis the first global pharmaceutical client to join Euro RSGC Worldwide.
In October, Euro RSCG won the $100m (£52.5m) creative account for Boniva, the drug used in the treatment of osteoporosis, which is jointly owned by Glaxo SmithKline and Hoffmann-LaRoche.